Umthombo Springs Business Plan — The Two-Series Funding Structure
Umthombo is deliberately raising in two stages rather than one. The reason is risk sequencing: the technical risks in this business, spring yield,…
The Two-Series Funding Structure
Jump to section
- Overview & contents
- Important Notice & Disclaimer
- Executive Summary
- The Company & the Water Source
- Market Analysis
- Products & Unit Economics
- Production & Operations
- Route to Market
- Quality, Certification & Compliance
- Sustainability & Water Stewardship
- Transformation & Community
- Management & Governance
- The Two-Series Funding Structure
- Series A Funding Adequacy
- Implementation Roadmap
- Competitive Positioning
- Financial Plan & Projections
- Capital Structure & Dilution
- Investor Returns & Sensitivity
- Risk Analysis & Independent Findings
- SWOT & Strategic Analysis
- Exit Strategy
- Key Performance Indicators
- Conclusion & The Investment Ask
- Annexure A: Detailed Financial Statements
- Annexure B: Assumptions Book
- Annexure C: Scenario & Sensitivity Detail
- Annexure D: Export Operations Manual
- Annexure E: Regulatory & Certification Register
- Annexure F: Series A & B Term Framework
- Annexure G: Detailed Risk Register
- Annexure H: Data Room Index
- Annexure I: Glossary & Investor Questions
Umthombo is deliberately raising in two stages rather than one. The reason is risk sequencing: the technical risks in this business, spring yield, licensing, plant commissioning, product certification, are concentrated in the first eighteen months and are resolvable with a comparatively modest amount of capital. The commercial risks, export channel development, working capital, brand building in destination markets, require substantially more capital but should only be funded once the technical risks are behind the business.
A single R133 million round at inception would price the entire risk of the business at its most uncertain point, diluting founders and early investors heavily for capital that could not be productively deployed for two years. Staging means Series A investors take the technical risk at a R36 million pre-money valuation, and Series B investors take the scale-up risk at a R135 million pre-money valuation, a 2.05 times step-up that rewards the first round for the risk it actually carried. This is textbook venture structuring, and the milestone gates between the rounds are specific and testable rather than aspirational: plant commissioned and SANS-compliant, domestic listings secured, FSSC 22000 achieved, and export trial shipments completed and repeated.
11.1 Series A — build and prove
|
Term |
Detail |
|---|---|
|
Total round |
R48.0 million |
|
Structure |
R30.0 million equity subscription; R18.0 million asset finance secured on the bottling line |
|
Pre-money valuation |
R36.0 million, reflecting the water use licence, lease, hydrogeological work, permitting and assembled team |
|
Post-money valuation |
R66.0 million |
|
Investor equity |
45.5%, with a 10% employee option pool created at close |
|
Instrument |
Ordinary shares with standard preference: 1x non-participating liquidation preference, anti-dilution on a broad-based weighted average basis |
|
Board |
One investor-nominated director; reserved matters schedule |
|
Milestones to Series B |
Plant commissioned and SANS-compliant; domestic listings secured; FSSC 22000 certification achieved; first export trial shipments completed and repeated |
11.2 Series B — scale export
|
Term |
Detail |
|---|---|
|
Total round |
R85.0 million |
|
Timing |
Targeted month 24, conditional on the Series A milestones |
|
Structure |
R60.0 million equity subscription; R25.0 million term debt and asset finance |
|
Pre-money valuation |
R135.0 million — a 2.05x step-up on the Series A post-money |
|
Post-money valuation |
R195.0 million |
|
Investor equity |
30.8% |
|
Use of funds |
Premium glass line, PET capacity uplift, export working capital, destination market registration and certification, brand and trade investment |
|
Pro-rata rights |
Series A investors hold pro-rata participation rights in Series B |